GE Healthcare Technologies Inc. (GEHC) stock soared 5.12% in the pre-market session on Thursday, following the company's strong fourth quarter 2024 earnings results.
The medical technology company reported adjusted earnings per share of $1.45 for Q4, surpassing analyst estimates of $1.26. Revenue grew 2% year-over-year to $5.32 billion, narrowly missing expectations of $5.33 billion.
GE Healthcare saw double-digit revenue growth in its Pharmaceutical Diagnostics and Advanced Visualization Solutions segments. The company highlighted robust momentum in orders, backlog levels, and book-to-bill ratios during the quarter.
For the full year 2025, GE Healthcare provided upbeat adjusted EPS guidance of $4.61 to $4.75, higher than the consensus estimate of $4.66. The company cited continued strong demand for its products and services, although it expects some headwinds in China due to a delay in stimulus measures and an ongoing anti-corruption campaign.
Investors cheered GE Healthcare's better-than-expected profit performance and optimistic outlook, driving the stock's pre-market rally. The company's solid execution and growth prospects in key healthcare segments appear to be fueling the stock's momentum.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.